PTC Therapeutics shifts to growth with strong Sephience launch and $1.9B cash cushion

PTC Therapeutics is evolving from a legacy rare disease company to a growth-focused business, driven by the successful launch of Sephience. The new product's rapid uptake is compensating for declines in its Duchenne muscular dystrophy (DMD) franchise, with Q1 2026 revenues up 47% year-over-year and strong patient onboarding. Its partnership with Novartis on votoplam for Huntington's disease offers promising late-stage potential. With $1.9 billion in cash, PTC has strategic flexibility and reduced near-term dilution risk. Despite these strengths, the company trades at a significant valuation discount compared to peers, presenting a potential investment opportunity.